Adaptive Biotechnologies Corporation (ADPT)

Market Cap	1.25B
Revenue (ttm)	178.96M
Net Income (ttm)	-159.49M
Shares Out	148.58M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,769,722
Open	8.58
Previous Close	8.66
Day's Range	8.37 - 8.74
52-Week Range	2.28 - 9.01
Beta	1.53
Analysts	Strong Buy
Price Target	9.40 (+11.64%)
Earnings Date	May 6, 2025

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as M...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 27, 2019
• Employees: 619
• Stock Exchange: NASDAQ
• Ticker Symbol: ADPT
• Website: https://www.adaptivebiotech.com

Financial Performance

In 2024, Adaptive Biotechnologies's revenue was $178.96 million, an increase of 5.10% compared to the previous year's $170.28 million. Losses were -$159.49 million, -29.19% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for ADPT stock is "Strong Buy." The 12-month stock price forecast is $9.4, which is an increase of 11.64% from the latest price.

Price Target

$9.4

(11.64% upside)

Analyst Consensus: Strong Buy